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bjectives We sought to compare outcomes for percutaneous coronary intervention patients undergo-
ng complete revascularization (CR) and incomplete revascularization (IR) in the drug-eluting stent era.
ackground There have been relatively few studies that have examined the impact of IR in patients
ndergoing coronary stenting, particularly in the era of drug-eluting stents.
ethods New York State’s Percutaneous Coronary Intervention Reporting System was used to iden-
ify 11,294 stent patients with multivessel disease undergoing either IR or CR in 39 hospitals be-
ween October 1, 2003, and December 31, 2004. These patients were followed through December
1, 2005, and IR patients were subdivided based on the number of IR vessels and presence of a
hronic total occlusion. Risk-adjusted mortality and mortality/myocardial infarction (MI) for CR and IR
atients were compared at 18 months.
esults Incomplete revascularization was performed in a total of 7,795 patients (69.0%). Incomplete
evascularization was associated with higher 18-month mortality (adjusted hazard ratio [HR]: 1.23,
5% conﬁdence interval [CI]: 1.04 to 1.45) and higher 18-month MI/mortality (adjusted HR: 1.27, 95%
I: 1.09 to 1.47). The risk-adjusted survival rates for CR and IR were 94.9% and 93.8% (p  0.01). The
isk-adjusted survival/freedom from MI rates were 93.3% and 91.7% (p  0.002). Patients with 2 dis-
ased vessels unattempted with a total occlusion were at highest risk (adjusted survival HR: 1.44,
5% CI: 1.14 to 1.82, risk-adjusted survival 94.9% vs. 92.9%, p  0.002; and adjusted survival/free-
om from MI: 1.50, 95% CI: 1.21 to 1.86, rates 93.3% vs. 90.3%, p  0.001).
onclusions Patients undergoing coronary stenting who receive IR experience more adverse out-
omes even in the era of drug-eluting stents. This has implications for choice of procedure and
ost-procedural monitoring. (J Am Coll Cardiol Intv 2009;2:17–25) © 2009 by the American College
f Cardiology Foundation
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18nlike coronary artery bypass graft (CABG) surgery, where
ost patients are completely revascularized and where
omplete revascularization (CR) has been demonstrated to
e associated with better long-term outcomes, the strategy
or multivessel disease patients undergoing percutaneous
oronary interventions (PCI) frequently involves incomplete
evascularization (IR). In IR, balloon angioplasty and stent
lacement are performed (or performed successfully, de-
ending on the definition) on only some of the patient’s
iseased vessels. Reasons for not attempting all diseased
essels may include the presence of 1 or more chronic total
cclusions, the presence of serious medical conditions such
s severe left ventricular dysfunction, or the decision to treat
nly the “culprit lesion” that is thought to be responsible for
he patient’s symptoms.
Although multiple studies (1–17) have compared out-
omes of patients who have been completely and incom-
letely revascularized with PCI, few of these are recent.
Most of these studies were con-
ducted before the introduction
of coronary stenting, and many
were conducted in the context of
randomized trials in which in-
completely revascularized patients
were monitored more closely
than they would be under nor-
mal circumstances.
The purpose of this study was
to compare outcomes (18-month
mortality, 18-month mortality/
myocardial infarction [MI]) for
patients with multivessel disease
who were completely and in-
completely revascularized using
stents in the era following the
introduction of drug-eluting
tents (DES). When significant differences were found, we
hen focused on groups of IR patients for whom the
utcomes were the worst.
ethods
atabases. Data were obtained from New York State’s
ercutaneous Coronary Interventions Reporting System
PCIRS), a mandatory registry in New York, which was
nitially developed in 1992, that contains detailed informa-
ion for each patient undergoing PCI in the state on
emographics; pre-procedural risk factors; peri-procedural
omplications; types of devices used; lesions diseased; dates
f admission, discharge, and procedure; discharge disposi-
ion and destination; and hospital and operator identifiers.
lso, PCIRS contains information on diseased and at-
empted lesions, including regions of the heart, whether or
bbreviations
nd Acronyms
ABG  coronary artery
ypass graft
R  complete
evascularization
TO  chronic total
cclusion
ES  drug-eluting stent(s)
R  incomplete
evascularization
I  myocardial infarction
CI  percutaneous
oronary interventions
CIRS  Percutaneous
oronary Intervention
eporting Systemot a lesion was attempted, and pre- and post-procedural Ctenosis. These data are matched to New York administra-
ive data and are audited by the New York State Depart-
ent of Health’s utilization review agent to ensure com-
leteness and accuracy.
The PCIRS data were matched to New York’s vital
tatistics data so that patients could be followed after
ischarge for evidence of subsequent death. Also, PCIRS
ata were matched to data in New York’s acute care
dministrative database, the Statewide Planning and Re-
earch Cooperative System, to identify stent patients read-
itted to New York hospitals with a principal diagnosis of
I using unique patient identifiers. Furthermore, data from
ew York’s Cardiac Surgery Reporting System was used
long with PCIRS data to identify repeat revascularizations
fter discharge through December 31, 2005.
atients. Patients in the study included all patients with
ultivessel disease (defined as stenosis70% in at least 2 of
he 3 main coronary arteries) who underwent stenting in
onfederal New York State hospitals between October 1,
003, and December 31, 2004, and followed through
ecember 31, 2005, except patients with previous revascu-
arization (n  5,642), left main disease (defined as stenosis
50%, n  189), an acute MI during the 24-h period
efore undergoing PCI (n  2,254); CABG surgery fol-
owing PCI during the index admission (n  44); and
on–New York patients (n  430). The study was limited
o New York residents because the New York Vital Statis-
ics Death File only applies to residents of the state.
“Complete revascularization” was defined as successfully
ttempting all diseased (70% stenosis) lesions in major
picardial coronary vessels (proximal, mid, and distal seg-
ents; major left anterior descending diagonals; and cir-
umflex marginal branches) with PCI either during the
ndex hospitalization or at any time within 30 days after
ischarge from the index hospitalization for PCI but before
uffering a new MI. Success was defined as a reduction in
tenosis of at least 20% and a residual stenosis of less than
0%. Patients not meeting the definition of CR were
efined to have IR.
nd points. End points in the study were 18-month mor-
ality, mortality/MI, subsequent CABG (new admission
ore than 30 days after discharge), and repeat PCI (new
dmission more than 30 days after discharge). Myocardial
nfarctions occurring after PCI during the index admission
ere defined in PCIRS as new Q waves and a rise in cardiac
nzyme to at least 2.5 times the normal range. Myocardial
nfarctions occurring after discharge were obtained using
tatewide Planning and Research Cooperative System data
nd were defined as readmissions with International Classi-
cation of Diseases-Ninth Revision-Clinical Modification code
10.x1 as a principal diagnosis. All adverse outcomes were
isk-adjusted to account for differences in baseline risk of
R and IR patients.
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19tatistical analysis. Differences in baseline characteristics
etween CR and IR patients (e.g., demographics, comor-
idities, left ventricular function, hemodynamic state, ves-
els diseased, symptoms) were examined using Fisher exact
nd chi-square tests.
To test for risk-adjusted differences in mortality and
ortality/MI, stepwise Cox proportional hazards survival
odels with a robust covariance matrix that accounts for
orrelation of survival times for individuals within a hospital
r operator cluster (18) were developed for each adverse
utcome measure after having confirmed that the propor-
ional hazards assumption was justified (19). Candidate
ndependent variables included the patient risk factors
vailable in PCIRS (demographics, left ventricular function,
I more than 1 day before the procedure, and numerous
omorbidities). Type of revascularization (CR, IR) was used
n each model as an independent variable with IR treated as
he indicator variable, and the CR/IR adjusted hazards
atios were obtained by exponentiation of the coefficient of
hat variable. Adjusted survival curves were constructed for
R and IR for each of the 2 outcomes using the Cox
roportional hazards survival models and methods for cal-
ulating adjusted survival (20).
Different types of IR (1-vessel IR/no total occlusion;
-vessel IR/total occlusion; 2-vessel IR/no total occlusion;
-vessel IR/at least 1 total occlusion) were then compared
ith CR for each adverse outcome by creating similar
roportional hazards models with each of the IR types as a
inary indicator variable and CR as the reference. Patients
ith total occlusions were examined separately because they
re in danger of having worse longer-term outcomes and
ecause IR may sometimes be justified in these patients
hen there is no viable myocardium to be preserved.
Cox proportional hazards survival models were also used
o test for significance of hazards ratios for 4 subsets of
atients: 1) patients who were at least 80 years old; 2) were
iabetics; 3) had ejection fractions of 40% or less; and 4) had
eft anterior descending artery disease. For subsequent
ABG surgery and repeat PCI, log-rank tests were used to
ompare Kaplan-Meier survival estimates of survival differ-
nces between CR and each type of IR.
To test for selection bias, a propensity model was devel-
ped (21,22). The risk factors in Table 1 were used as
ndependent variables in a logistic regression model with a
inary dependent variable representing IR. Also, the per-
entage of patients in which CR was attempted in the
ospital in which each patient underwent stenting was used
s independent variable in the model in case outcomes were
elated to the quality of the hospital. The propensity score
as subdivided into quartiles and 18-month hazards ratios
or IR/CR were examined across quartiles for mortality and
ortality/MI to determine if there was any trend or majorifference based on the tendency to use CR versus IR. All Nests were 2-sided and conducted at the 0.05 level, and all
nalyses were conducted in SAS 9.1 (SAS Institute, Cary,
Table 1. Baseline Characteristics of Stent Patients (N  11,294)
Variable
CR
(n  3,499)
IR
(n  7,795) p Value
Age, yrs 0.001
50 10.5 9.0
50–59 24.0 22.1
60–69 27.9 27.3
70–79 26.4 27.1
80 11.2 14.5
Gender 0.71
Male 66.8 67.1
Female 33.2 32.9
Race and ethnicity 0.001
Hispanic 7.5 10.1
Non-Hispanic Black 7.1 11.2
Non-Hispanic White 79.4 71.7
Other 5.9 7.0
Ejection fraction, % 0.001
19 0.3 1.1
20–29 2.3 3.9
30–39 5.1 7.6
40 87.1 82.2
Missing 5.1 5.2
Previous MI 0.001
1–7 days 19.3 20.1
8–20 days 1.8 2.9
21 days 7.7 14.7
No MI prior to procedures 71.2 62.4
Cerebrovascular disease 7.3 8.2 0.08
Peripheral arterial disease 5.1 8.3 0.001
Hemodynamically unstable or shock 0.3 0.3 1.0
Congestive heart failure 0.001
None 91.9 88.2
This admission 6.0 8.6
Before this admission 2.1 3.2
Malignant ventricular arrhythmia 0.4 0.5 0.45
Chronic obstructive pulmonary disease 6.1 6.8 0.15
Diabetes 28.3 34.3 0.001
Renal failure 0.001
Requiring dialysis 2.0 2.6
Creatinine 2.5 mg/dl 0.9 1.7
No renal failure 97.1 95.7
Number of diseased vessels
(stenosis 70%)
0.001
2 90.1 68.4
3 9.9 31.6
Type of stents implanted 0.001
Bare-metal stents only 8.1 13.7
Drug-eluting stents only 75.5 80.2
Other 16.5 6.1
CR complete revascularization; IR incomplete revascularization; MImyocardial infarction.orth Carolina).
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20esults
total of 7,795 patients (69.0%) were classified as IR patients.
he range across the 39 hospitals in percentage of patients who
ere IR was 45% to 89%. Of the IR patients, 48.9% had
-vessel IR with no chronic total occlusion (CTO), 22.1% had
-vessel IR with a CTO, 15.8% had 2-vessel IR with no CTO,
nd 13.1% had 2-vessel IR with a CTO.
Significant predictors of IR include advanced age, race
higher rates for African Americans and Hispanics), lower
jection fractions, previous MI, and several comorbidities:
eripheral arterial disease, congestive heart failure, diabetes,
enal failure, 3-vessel disease, and the exclusive use of
are-metal stents (see Table 1).
Table 2 indicates that after adjustment for differences in
aseline characteristics between IR and CR patients, IR was
ssociated with higher 18-month mortality (adjusted hazard
atio [HR]: 1.23, 95% confidence interval [CI]: 1.04 to
.45) and higher 18-month MI/mortality (adjusted HR:
.27, 95% CI: 1.09 to 1.47). The respective risk-adjusted
urvival rates (Fig. 1A) for CR and IR were 94.9% and
3.8% (p  0.01). The risk-adjusted survival/freedom from
I rates (Fig. 2A) were 93.3% and 91.7% (p  0.002).
There were 2 IR groups for which IR patients had signifi-
antly higher mortality: patients with 1-vessel disease with no
cclusion (adjusted HR: 1.23, 95% CI: 1.02 to 1.48), risk-
djusted survival 94.9% versus 93.8%, p  0.03 (Fig. 1B), and
atients with 2 diseased vessels unattempted with a total
cclusion (adjusted HR: 1.44, 95% CI: 1.14 to 1.82), risk-
djusted survival 94.9% versus 92.9%, p  0.002 (Fig. 1B).
Incomplete revascularization patients had significantly
igher mortality/MI rates for 3 of the 4 groups of IR patients:
-vessel IR with no total occlusion (adjusted HR: 1.22, 95%
I: 1.04 to 1.44), risk-adjusted survival/freedom from MI,
3.3% versus 91.9%, p  0.02; 2-vessel IR with no total
cclusion (adjusted HR: 1.34, 95% CI: 1.04 to 1.73), risk-
Table 2. Adjusted HR (IR and IR Subgroups vs. CR) and 95% CI for 18-Mon
Patient Group
No. of
Cases
Mean
Length of
Follow-up
(Months) No. of Event
CR 3,499 19.0 165
IR 7,795 18.9 551
Subgroups of IR
1 IR vessel with no total occlusion 3,815 18.9 239
1 IR vessel with total occlusion 1,725 19.1 112
2 IR vessels with no total occlusion 1,233 19.1 92
2 IR vessels with total occlusion 1,022 18.4 108
Note that all the significant predictorswere also significant predictors after adjusting for propensity s
cerebrovascular disease, peripheral arterial disease, hemodynamic state, congestive heart failure, ch
variables for the mortality model and diabetes.
CI confidence intervals; HR hazard ratios; other abbreviations as in Table 1.djusted survival/freedom from MI, 93.3% versus 91.3%, p  e.03; and 2-vessel IR with total occlusion (adjusted HR: 1.50,
5% CI: 1.21 to 1.86), risk-adjusted survival/freedom from
I, 93.3% versus 90.3%, p  0.001 (Fig. 2B).
For stent patients with CR, a total of 1.6% had subse-
uent CABG surgery within 18 months (Kaplan-Meier
stimate). Compared with CR, the need for subsequent
ABG surgery was significantly higher for patients with
-vessel IR with a total occlusion (3.4%, p  0.001) and
atients with 2-vessel IR and no total occlusion (2.7%, p 
.02). Patients with 1-vessel IR with or without total
cclusions did not have significantly different rates of
ubsequent CABG surgery (2.2% and 1.5%, respectively).
A total of 13.5% of stent patients with CR had repeat
CI within 18 months. Patients with 2-vessel IR with and
ithout a total occlusion both had higher rates of repeat
CI (20.3% and 29.5%, respectively, p  0.001 for both
roups). Patients with 1-vessel IR and a total occlusion did
ot have a significantly different rate of repeat PCI (11.7%,
 0.09) and patients with 1-vessel IR and no total
cclusion had a significantly higher rate (22.1%, p 0.001).
Of the patients in the study, 9,936 (88.0%) had at least 1
ES. Of those patients, IR patients were trending toward
igher 18-month mortality compared with 18-month mor-
ality in CR patients (adjusted HR: 1.21, 95% CI: 0.99 to
.46) and IR had higher mortality/MI (adjusted HR: 1.30,
5% CI: 1.09 to 1.53). Two IR subgroups had significantly
igher mortality, with the highest HR for patients with 2
iseased vessels unattempted with a total occlusion (adjusted
R: 1.34, 95% CI: 1.01 to 1.77). Of the 4 groups, 3 groups
ad higher mortality/MI rates for IR patients, with the largest
R for patients with 2 diseased vessels unattempted with a
otal occlusion (adjusted HR: 1.49, 95% CI: 1.17 to 1.89).
With respect to selected subgroups of patients, Table 3
ndicates that there were no significant differences in adjusted
ortality between CR and IR for diabetics, patients with
rtality and Mortality/MI by Subgroups of IR
Mortality Mortality/MI
Adjusted HR*
(95% CI) p Value No. of Events
Adjusted HR†
(95% CI) p Value
Reference 216 Reference
1.23 (1.04–1.45) 0.01 736 1.27 (1.09–1.47) 0.002
1.23 (1.02–1.48) 0.03 316 1.22 (1.04–1.44) 0.02
1.11 (0.87–1.42) 0.39 145 1.14 (0.92–1.41) 0.24
1.18 (0.89–1.56) 0.26 132 1.34 (1.04–1.73) 0.03
1.44 (1.14–1.82) 0.002 143 1.50 (1.21–1.86) 0.001
djusted for age, race/ethnicity, ejection fraction, history ofmyocardial infarctionprior toprocedure,
structive pulmonary disease, renal failure, and type of stents implanted.†Adjusted for all controlth Mo
s
core. *A
ronic objection fractions that were at most 40%, or patients at least 80
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21ears old. Patients with a diseased left anterior descending
rtery fared better with CR (adjusted HR: 1.25, 95% CI: 1.02
o 1.54). There were no significant differences between CR and
R in mortality/MI rates for patients with ejection fractions
hat were at most 40%, but IR patients who were diabetic or
ho had left anterior descending artery disease had signifi-
antly higher rates (adjusted HR: 1.29, 95% CI: 1.01 to 1.65,
nd adjusted HR: 1.28, 95% CI: 1.05 to 1.56, respectively),
nd IR patients who were age 80 years or older had borderline
igher rates (adjusted HR: 1.32, 95% CI: 1.00 to 1.75).
In the propensity model, the C statistic was in the
ppropriate range—reasonably high (0.73) but not so high
s to be indicative of 2 groups of patients with no common-
lity. Hazards ratios in order of increasing tendency to use
Figure 1. Adjusted 18-Month Survival Curves
(A and B) Adjusted for age, race/ethnicity, ejection fraction, history of myocardial
hemodynamic state, congestive heart failure, chronic obstructive pulmonary diseaR for the quartiles related to mortality were 1.14, 1.24, p.23, and 1.01. Hazards ratios for mortality/MI were 1.42,
.12, 1.35, and 1.01. Although the HR in the last quartile
or each outcome was the lowest, there was no evidence of
trend toward lower HRs with increasing tendency to use
R. Also, all patients in the last quartile were removed from
he database for each outcome, and 2 new sets of analyses
ere conducted. The resulting HRs were nearly identical to
he original HRs (1.23 for mortality compared with the
riginal 1.23, and 1.27 for mortality/MI compared with
he original 1.29).
iscussion
urprisingly few studies have compared outcomes for
ion prior to procedure, cerebrovascular disease, peripheral arterial disease,
al failure, and type of stents implanted. IR  incomplete revascularization.infarctatients completely and incompletely revascularized for
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22CI. Most of those pre-date the use of stents, particu-
arly DES.
Most earlier studies that examined the impact of IR for
CI were considerably smaller and were conducted before
he DES era. Some of these studies found no differences in
utcomes between IR and CR patients, but these studies
ere quite small. For example, Mariani et al. (1) and
jsselmuiden et al. (17) found that there was no difference in
ajor adverse cardiac event rates between CR and IR
atients, but both studies had very low statistical power. In
he Ijsselmuiden et al. (17) study, major adverse cardiac
vent rates were found to be the same at 4.6  1.2 years
34.6% for CR vs. 40.4% for IR) and repeat PCI rates were
lso found to be the same (21.2% vs. 31.2%, p  0.06).
Figure 2. Adjusted 18-Month Curves for Survival Free From MI
(A and B) Adjusted for age, race/ethnicity, ejection fraction, history of myocar
disease, hemodynamic state, congestive heart failure, chronic obstructive pulm
revascularization.owever, the lack of statistical significance may be because phere were only 108 CR patients and 111 IR patients in the
tudy. Similarly, the Mariani et al. (1) study had only 49 CR
atients and 159 IR patients.
Of the other studies, 2 found significantly higher rates of
ubsequent CABG surgery among IR patients. In the
RTS (Arterial Revascularization Therapies Study) trial,
an den Brand et al. (3) found that after 1 year, patients
ndergoing IR with stenting experienced significantly lower
vent-free survival (freedom from death, MI, cerebrovascu-
ar accident, and repeat revascularization) than stent patients
ith CR did (69.4% vs. 76.6%, p  0.05), and that this
ifference was due to a higher use of subsequent CABG
urgery (10.0% vs. 2.0%, p  0.05).
Bourassa et al. (4) found in the BARI (Bypass Angio-
farction (MI) prior to procedure, cerebrovascular disease, peripheral arterial
disease, renal failure, and type of stents implanted. IR  incompletedial in
onarylasty Revascularization Investigation) trial that among
n
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23ondiabetic patients who were candidates for CABG sur-
ery, 5-year rates of death, cardiac death, repeat revascular-
zation, and angina were similar in all PCI patients with CR
nd IR. However, there was a trend for higher rates of
reedom from subsequent CABG surgery among CR pa-
ients (70.3% vs. 64.0%, p  0.08).
Three other studies found that CR was superior to IR
ith regard to mortality as well as other outcomes. In a
ingle center observational study, Kalarus et al. (13) found
hat among PCI patients with acute MI, remote mortality
18.5% vs. 7.2%, p 0.001) and major adverse cardiac event
53.1% vs. 24.3%, p  0.001) rates were both higher for IR
atients than for CR patients.
Nikolsky et al. (5) examined 658 consecutive diabetic
atients (94 CR patients and 258 IR patients) who under-
ent PCI and found that CR patients had a significantly
igher survival rate at 5 years (94.5% vs. 83.0%, p  0.001).
lso, the rate of MI-free survival was significantly higher
or CR patients (92.9% vs. 79.9%, respectively).
An earlier study in New York also identified better
utcomes for CR patients. In an era before the use of DES,
annan et al. (12) found that patients undergoing bare-
etal stenting for whom IR was intended were significantly
ore likely to die at any time than other patients (adjusted
R: 1.15, 95% CI: 1.01 to 1.30). Furthermore, IR patients
ith total occlusions and 2 or more vessels IR comprised
4% of all IR patients and had the highest risk compared
ith CR patients (adjusted HR: 1.36, 95% CI: 1.12 to
.36). Incomplete revascularization patients with a single
otal occlusion IR comprised 21% of all IR patients and had
he second highest risk (adjusted HR: 1.35, 95% CI: 1.14
o 1.59).
The study reported here found that that the percentage of
tent patients who were classified as IR in the era of DES
as 69.0%. Incomplete revascularization was associated
Table 3. Adjusted HR (IR vs. CR) and 95% CI for Mortality and Mortality/M
Patient Group
Completeness of
Revascularization
No. of
Cases
Mean
Length of
Follow-up
(Months) No. of
Diabetes CR 991 18.7 6
IR 2,673 18.7 21
Ejection fraction 40% CR 273 18.4 3
IR 976 18.1 14
Age 80 yrs CR 393 18.2 4
IR 1,132 18.1 18
Left anterior descending
artery disease
CR 2,634 18.7 12
IR 3,362 18.5 25
Note that all the significant predictorswere also significant predictors after adjusting for propensity s
cerebrovascular disease, peripheral arterial disease, hemodynamic state, congestive heart failure, c
variables for the mortality model and diabetes.
Abbreviations as in Tables 1 and 2.ith significantly higher 18-month mortality (adjusted HR: a.23, 95% CI: 1.04 to 1.45) and higher 18-month MI/
ortality (adjusted HR: 1.27, 95% CI: 1.09 to 1.47). The
isk-adjusted survival rates for CR and IR were 94.9% and
3.8% (p  0.01) and the risk-adjusted survival/freedom
rom MI rates were 93.3% and 91.7% (p  0.002).
Subsequent analyses subdivided patients on the basis of
he number of diseased vessels IR and on the basis of
hether they had total occlusions. Patients with total
cclusions were examined separately because they are in
anger of having worse longer-term outcomes and because
R may sometimes be justified in these patients when there
s no viable myocardium to be preserved. Because we were
nable to identify when this is the case, we wanted to see if
he benefit of CR relative to IR was restricted to patients
ith total occlusions. The results demonstrated that al-
hough the benefit of CR was highest for patients with 2
iseased vessels IR and a total occlusion, patients with
-vessel IR and no total occlusion had significantly higher
ortality and mortality/MI than CR patients did, and
atients with 2 vessels IR and no total occlusion had
ignificantly higher mortality/MI than CR patients did.
tudy limitations. There are a few caveats to the study.
irst, it is an observational study, and differences among
atients in characteristics related to outcomes may have
een the reason for differences in outcomes between CR and
R. This potential bias was controlled for by risk-adjusting
he outcomes by using patient characteristics that were
ignificantly related to the outcomes. Also, a propensity
nalysis was used to test for selection bias, and the conclu-
ions were that there was no tendency for the outcome
dvantages for CR patients to have been concentrated in the
roup of patients who were far more likely to receive CR.
owever, patient characteristics such as cancer and the need
or noncardiac surgery were not available in the database,
Selected Subgroups of Patients
Mortality Mortality/MI
Adjusted HR*
(95% CI) p Value No. of Events
Adjusted HR†
(95% CI) p Value
Reference 84 Reference
1.11 (0.85–1.44) 0.46 317 1.29 (1.01–1.65) 0.04
Reference 36 Reference
1.18 (0.78–1.79) 0.42 183 1.29 (0.88–1.89) 0.20
Reference 50 Reference
1.28 (0.94–1.73) 0.12 218 1.32 (1.00–1.75) 0.05
Reference 166 Reference
1.25 (1.02–1.54) 0.04 338 1.28 (1.05–1.56) 0.02
djusted for age, race/ethnicity, ejection fraction, history ofmyocardial infarctionprior toprocedure,
bstructive pulmonary disease, renal failure, and type of stents implanted. †Adjusted for all controlI for
Events
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24ikely to be present in IR patients, this introduces an
ncontrolled bias (23).
Moreover, we were unable to determine why CR was not
ttempted, and many patients may not have undergone CR
ecause they were not amenable to it, such as patients with
diseased vessel that supplies an infarcted territory, or
ecause it was not judged to be beneficial. However, as
oted previously, even IR patients without total occlusions
ad significantly worse outcomes than CR patients did. The
ery low percentage of CR (31%) and the large variation in
R rates across the 39 hospitals in the study (from 45% to
9%) may be a result of differences in patient mix across
ospitals, but we believe it suggests that there was consid-
rable variation in practice pattern and that many more CRs
ould have been attempted and would have been beneficial.
It is conceivable that a planned CR may have been
borted and turned into an IR when the procedure was more
omplex than anticipated or if adverse events occurred. To
ccount for this possibility, we repeated the analyses with
ny attempted CR assigned to the CR group rather than the
R group. However, the outcomes were essentially the same
ecause only 6.8% of the attempted CRs were unsuccessful.
or example, the respective risk-adjusted 18-month survival
ates for CR and IR when success is part of the definition
ere 94.9% and 93.8%, and when success was not part of
he definition of CR, these rates were 94.7% and 93.9%.
It is also possible that the period we used to allow for CR
hen procedures were staged (30 days) was too short, but
e found here and elsewhere (12) that extending that period
o 60 days did not change the essence of the findings. We
ere unable to control for differences in post-procedural use
f dual antiplatelet therapy, but there is no reason to believe
here should be utilization differences between CR and IR
atients, particularly because the time frame was the same
or both groups.
In addition, there is a possibility that the results could be
iased as a result of incomplete follow-up of post-discharge
Is and deaths. New York state vital statistics data were
sed to identify patients who died after discharge. Because
f this, the study was limited to patients residing in New
ork at time the procedure was performed. We were not
ble to capture deaths or subsequent revascularizations for
I for patients who moved to another state or after
ischarge, but results from a similar study comparing
utcomes of CABG surgery and PCI in New York indicate
hat very few deaths are missed because of patients moving
ut of state (24). Also, it seems unlikely that the percentages
f CR and IR patients who move out of state would differ
ubstantially.
Another caveat is that DES use in the time interval
hosen for analysis was not mature, and bias of DES versus
are-metal stent use existed, which may have affected the
tudy outcomes.onclusions
s noted by Ong and Serruys (15), “complete revascular-
zation is an important factor in the decision-making
rocess that requires careful thought before a patient is
ecommended for either treatment option. The goal should
lways be complete revascularization, because the overall
rend supports it, whether the treatment choice is surgery or
ercutaneous intervention.” The results reported here sug-
est that if CR is not being contemplated for PCI, outcomes
ay not be optimal. Also, although it is not always clear
efore the procedure which patients are amenable to CR,
ur results suggest that if it is not achieved, it may be wise
o monitor those patients more intensively after discharge.
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